Intragastric Balloons Market | USD 142.09 Million by 2034
The global intragastric balloons market size was exhibited at USD 45.75 million in 2024 and is projected to hit around USD 142.09 million by 2034, growing at a CAGR of 12.0% during the forecast period of 2024 to 2034.
| Report Coverage | Details |
| Market Size in 2024 | USD 51.24 Million |
| Market Size by 2033 | USD 142.09 Million |
| Growth Rate From 2024 to 2033 | CAGR of 12.0% |
| Base Year | 2024 |
| Forecast Period | 2024-2034 |
| Segments Covered | Administration, Balloon Type, Filling Material, End-use, Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional Scope | North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
| Key Companies Profiled | Apollo Endosurgery, Inc.; Obalon Therapeutics, Inc.; Allurion Technologies, Inc.; Spatz3; Helioscopie; Endalis; MEDSIL; ReShape Medical, Inc.; Lexel Medical. |
The increasing prevalence of obesity is anticipated to drive market growth. Furthermore, the rise in demand for minimally invasive procedures is anticipated to further boost the market growth.
Obesity is a major health concern across the globe. The obesity pandemic is expected to continue increasing over the forecast period, thus fueling the market growth. For instance, according to the World Health Organization (2016) data, nearly 2 billion individuals were overweight, and out of which around 650 million were obese. In addition, it is estimated that, by 2025, 2.7 billion individuals will be overweight and around 1.0 billion will be obese.
Despite the high prevalence of obesity and the wide acceptance of weight-loss surgical procedures (such as gastric bypass and sleeve gastrectomy) by healthcare professionals, merely 1% or 2% of the obese population is eligible for these surgeries leading to high mortality due to obesity. For instance, according to World Health Organization data, globally, nearly 2.8 million individuals die each year due to obesity or overweight. This high mortality is anticipated to fuel demand for alternate and minimally invasive procedures such as an intragastric balloon.
The American Society for Metabolic and Bariatric Surgery (ASMBS) included the intragastric balloon in the list of procedures and devices approved by the society as a treatment option, in 2023. The sanction and endorsements of this treatment by the ASMBS is anticipated to increase the adoption of intragastric balloons.
The high costs and procedural complications associated with aspiration therapy and neuroblocking therapy is anticipated to increase the demand for intragastric balloons. Furthermore, the development of novel intragastric balloons to overcome the shortcomings of conventional balloons is anticipated to further boost market demand. For instance, the magnetic soft endoscopic capsule-inflated intragastric balloon developed in collaboration with Nanyang Technological University, Singapore, is a biocompatible, acid-resistant and robot system for weight loss, thus reducing the need for complex insertion tools and the likelihood of adverse effects.
The endoscopy segment dominated the market for the intragastric balloon and held the largest revenue share of 69.8% in 2024. Emerging endoscopic technologies are able to reproduce the few of the anatomic modifications performed during weight loss surgery and are equally effective. In addition, endoscopic technologies are less invasive and cost-effective when compared to bariatric surgery. These factors are anticipated to contribute towards segment growth.
The pill form segment is anticipated to witness lucrative growth over the forecast period. This can be attributed to the non-surgical nature of the technique, reversible treatment, and availability of swallowable capsule which enables easy ingestion and excretion of the intragastric balloon.
The saline-filled segment dominated the market for the intragastric balloon and held the largest revenue share of 71.1% in 2024 due to the high product availability and significant weight loss produced by these systems. The gas-filled intragastric balloons segment is anticipated to grow at a rapid pace over the forecast period. The adverse events reported due to the use of saline-filled intragastric balloons are driving the demand for alternatives such as gas-filled intragastric balloons.
The single segment dominated the market for the intragastric balloon and held the largest revenue share of 75.2% in 2024 and the triple segment is anticipated to witness lucrative growth over the forecast period. The single intragastric balloon segment held the largest revenue share owing to the availability of a large number of products in the market and scientific evidence supporting its safety and efficacy. The benefits offered by the existing triple balloon system, such as minimal downtime and fully reversible treatment, are anticipated to increase the demand for this type of intragastric balloon.
The hospital segment dominated the market for the intragastric balloon and held the largest revenue share of 45.0% in 2024. This can be attributed to the availability of skilled professionals and the presence of sophisticated equipment in hospital settings. In addition, the availability of a large number of weight-loss treatment options requiring hospital stay is anticipated to contribute towards segment share.
Ambulatory surgical centers are anticipated to witness rapid growth over the forecast period due to high costs of hospitalization, rise in demand for minimally invasive procedures and treatment options.
North America dominated the market and accounted for the largest revenue share of 40.0% in 2024 in the intragastric balloons market. The high prevalence of obesity, availability of skilled professionals, and high adoption of weight loss treatments are some of the major factors contributing to the growth of the market in this region.
In Asia Pacific, the market for the intragastric balloon is expected to expand at a rapid pace over the forecast period. An increase in the number of obese populations, rise in an unhealthy lifestyle, and availability of treatment at relatively low cost in this region are some of the major factors driving the market in the region.
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the global intragastric balloons market.
Administration
Balloon Type
Filling Material
End-use
By Region
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers